Welcome to our dedicated page for Heron Therapeutics SEC filings (Ticker: HRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Heron Therapeutics, Inc. (HRTX) SEC filings page provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. As a Nasdaq‑listed commercial-stage biotechnology company, Heron uses Forms 10‑K, 10‑Q, 8‑K, and proxy statements on Schedule 14A to report financial results, material events, and governance matters related to its acute care and oncology supportive care business.
Investors reviewing HRTX SEC filings can examine current reports on Form 8‑K that disclose items such as quarterly and year‑to‑date financial results, capital restructuring transactions, amendments to credit facilities with Hercules Capital, Inc., exchange and issuance of convertible senior unsecured promissory notes, private placements of common and preferred equity, and adoption of a Tax Benefit Preservation Plan intended to protect net operating loss carryforwards. Other 8‑K filings describe material agreements, manufacturing and supply arrangements with Patheon, office lease commitments for corporate headquarters, and changes in the composition of the Board of Directors.
Heron’s proxy statements on Schedule 14A provide detail on stockholder meetings, including special meetings to approve the issuance of common stock upon conversion of convertible notes and Series A Convertible Preferred Stock under Nasdaq Listing Rule 5635(d). These documents explain voting procedures, virtual meeting logistics, and the specific proposals presented to stockholders.
Through this page, users can also track governance and capital structure disclosures such as the creation of Series A Convertible Preferred Stock and Series B Preferred Stock, rights plans, and cooperation agreements with significant investors. Stock Titan enhances these filings with AI‑powered summaries that highlight key terms, financial implications, and governance changes, helping readers quickly understand complex agreements without replacing the full legal text. Real‑time updates from EDGAR ensure that new HRTX filings, including 10‑K annual reports, 10‑Q quarterly reports, and Form 4 insider transaction reports when available, are surfaced promptly for further analysis.
Heron Therapeutics director Adam Morgan reported an equity grant and updated holdings. On January 30, 2026, he acquired 53,960 shares of common stock at a price of $0 through restricted stock units that vest in full on January 30, 2027. After this grant, he directly beneficially owns 123,737 shares of common stock.
An additional 8,753,290 shares of common stock are reported as indirectly owned by Velan Capital Master Fund LP. Mr. Morgan may be deemed to beneficially own these securities through related entities but expressly disclaims beneficial ownership except to the extent of his pecuniary interest.
Heron Therapeutics EVP and CFO Ira Duarte reported an automatic conversion of restricted stock units into common shares. On January 31, 2026, 11,695 restricted stock units were converted into 11,695 shares of common stock at a price of $0 per share under a previously granted equity award.
After this transaction, Duarte directly owned 195,356 shares of common stock and held 140,332 restricted stock units. Each restricted stock unit represents the right to receive one share of common stock, vesting in 16 equal quarterly installments that began on January 31, 2025.
Heron Therapeutics executive William P. Forbes reported the vesting of restricted stock units (RSUs) into common shares. On January 31, 2026, 11,695 RSUs converted into 11,695 shares of common stock at an exercise price of $0.00 per share.
After this transaction, Forbes directly owned 181,773 shares of common stock and 140,332 RSUs. Each RSU represents the right to receive one share of common stock, and the RSUs vest in 16 equal installments beginning one quarter after the January 31, 2025 grant date.
Heron Therapeutics CEO Craig A. Collard, who also serves as a director, reported the vesting and conversion of 34,789 restricted stock units into an equal number of Heron common shares on January 31, 2026 via transaction code M.
Each restricted stock unit represents the right to receive one share of common stock, and these units vest in 16 equal installments beginning one quarter after the January 31, 2025 grant date. Following this transaction, Collard directly holds 571,710 shares of common stock and 417,464 restricted stock units, reflecting his ongoing equity compensation in the company.
The Vanguard Group filed a Schedule 13G reporting a passive ownership stake in Heron Therapeutics Inc. As of December 31, 2025, Vanguard reported beneficial ownership of 9,820,384 shares of Heron Therapeutics common stock, representing 5.35% of the outstanding class.
Vanguard reported no sole voting or dispositive power, with 1,238,163 shares subject to shared voting power and 9,820,384 shares subject to shared dispositive power. The filing states the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Heron Therapeutics.
The document notes that, following an internal realignment effective January 12, 2026, certain Vanguard subsidiaries or business divisions that pursue the same investment strategies may in the future report beneficial ownership separately on a disaggregated basis.
Heron Therapeutics executive William P. Forbes reported a routine equity vesting transaction. On 01/19/2026, 3,875 restricted stock units converted into an equal number of shares of Heron Therapeutics common stock, at an exercise price of $0.00 per unit. Following this conversion, Forbes directly held 30,994 restricted stock units and 170,078 shares of common stock. The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the original grant date of 01/19/2024, reflecting ongoing equity-based compensation rather than an open-market share sale.
Heron Therapeutics EVP and Chief Financial Officer Ira Duarte reported the vesting of restricted stock units and corresponding acquisition of common stock. On 01/19/2026, 3,875 restricted stock units were converted into 3,875 shares of common stock at a price of $0 per share in a transaction coded "M," which indicates an exercise or conversion. Following this transaction, Duarte directly held 183,661 shares of Heron Therapeutics common stock and 30,994 restricted stock units.
The footnotes explain that each restricted stock unit represents a right to receive one share of common stock and that the units vest in 16 equal quarterly installments starting one quarter after the grant date of 01/19/2024. This reflects routine equity compensation vesting for a senior executive rather than an open-market purchase or sale.
Heron Therapeutics, Inc. Chief Executive Officer Craig A. Collard reported an RSU vesting and share acquisition on 01/19/2026. A total of 13,797 restricted stock units were converted at an exercise price of $0 into 13,797 shares of common stock, reflecting previously granted equity compensation rather than an open-market purchase.
Each restricted stock unit represents a contingent right to receive one share of common stock, and these RSUs vest in 16 equal quarterly installments beginning one quarter after the 01/19/2024 grant date. Following this transaction, Collard directly held 110,375 restricted stock units and 536,921 shares of common stock.
Heron Therapeutics, Inc. filed a current report to share that it has issued a press release with preliminary financial results for the three months ended December 31, 2025 and for full-year 2025. The company furnished this press release as Exhibit 99.1 under a Regulation FD disclosure item, meaning it is being provided for informational purposes and is not treated as formally filed for liability purposes under Section 18 of the Exchange Act. The company also notes that this information will only be incorporated into other securities filings if specifically referenced.
Heron Therapeutics (HRTX)37,879 shares of common stock via restricted stock units, with 37,879 shares beneficially owned following the transaction. Each RSU equals one share and vests in 16 equal quarterly installments beginning one quarter after grant.
On the same date, the director received stock options for 227,272 shares at an exercise price of $1.1, expiring on 11/08/2035. These options vest in 48 equal monthly installments starting one month after grant.